おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
CalciMedica
company
About
CalciMedica is engaged in the discovery and development of small molecule drugs for the treatment of inflammatory and autoimmune disorders.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $21M
- Industries
- Health Care,Information Technology,Life Science
- Founded date
- Dec 1, 2006
- Number Of Employee
- 1 - 10
- Operating Status
- Active
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D, who identified Orai1 as the CRAC channel subunit in 2006.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$21M
CalciMedica has raised a total of
$21M
in funding over 2 rounds. Their latest funding was raised on
Mar 11, 2021 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 11, 2021 | Series D | $21M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
CalciMedica is funded by 1 investors.
Global health sciences venture fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series D |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
